Journal
ONCOIMMUNOLOGY
Volume 1, Issue 5, Pages 741-743Publisher
LANDES BIOSCIENCE
DOI: 10.4161/onci.19532
Keywords
bispecific antibodies; apoptosis; granzyme/perforin; cancer stem cells; gene-immunotherapy
Categories
Ask authors/readers for more resources
TRAIL selectively kills cancer cells while bispecific antibody EpCAMxCD3 guides effector lymphocytes to cancer cells. Arming of ex vivo constructed TRAIL-lymphocytes with EpCAMxCD3 enhances contact time and affinity between lymphocytes and tumor cells and enforces tumor elimination. This boosts endogenous immune responses and augments the effect of cytotoxic tumor therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
